OakChart

Tenax Therapeutics Inc

TENXHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

1.690.00 (0.00%)
2026-11-12 02:24 CET
Market cap
76.96 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-65.76 USD m
Free cash flow, TTM
-49.35 USD m
EPS diluted, TTM
-1.39
P/E
-
Compare

Price

TENX against its 20, 50 and 200-day averages
2050200earnings
5.0010.0015.0020.0032.8M65.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TENXclose 1.6920-day 1.7050-day 1.80200-day 9.531.6952w high

91.3% under the 52-week high of 19.40 on 9 Jul 2026. 52-week low 1.31 on 10 Aug 2026. Last 15 sessions, 28.0% high to low

Volume 0.17× normal · the line is the 50-bar volume average

Profile

TENX
52-week range, 2% of the way up
1.3119.40

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

IndexRUT
Employees16
IPOApr 04, 1994
Beta0.97
ATR, 14d0.15
Rel volume0.17
Short float14.11%
Insider own9.48%
Inst own79.42%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap76.96M
Enterprise Value-36.77M
Income-65.76M
Sales0.00M
Book/sh2.39
Cash/sh2.50
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees16
IPOApr 04, 1994

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.71
P/C0.68
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio14.01
Current Ratio14.01
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.39
EPS next Y-1.31
EPS next Q-0.36
EPS this Y-3.70%
EPS next Y5.89%
EPS next 5Y1.50%
EPS past 3/5Y86.93% 77.09%
Sales past 3/5Y- -
EPS Y/Y TTM-22.58%
Sales Y/Y TTM-
EPS Q/Q21.42%
Sales Q/Q-
EarningsNov 05 BMO
EPS/Sales Surpr.13.29% -

Ownership

Insider Own9.48%
Insider Trans-
Inst Own79.42%
Inst Trans13.11%
ROA-59.83%
ROE-64.20%
ROIC-60.52%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-0.44%
SMA50-6.23%
SMA200-82.26%
Trades-

Technical

Shs Outstand45.54M
Shs Float41.22M
Short Float14.11%
Short Ratio1.27
Short Interest5.82M
52W High19.40 -91.29%
52W Low1.31 29.01%
Volatility8.35% 8.18%
ATR (14)0.15
RSI (14)42.95
Beta0.97
Rel Volume0.17
Avg Volume4.58M
Volume761,055

Performance

Perf Week-6.63%
Perf Month5.62%
Perf Quarter-7.65%
Perf Half Y-85.81%
Perf YTD-86.14%
Perf Year-75.99%
Perf 3Y-86.46%
Perf 5Y-99.93%
Perf 10Y-100.00%
Recom1.80
Target Price10.29
Prev Close1.69
Price1.69
Change %0.00%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
Aug 31, 2026DowngradeGGuggenheimBuy → Neutral
Aug 11, 2026DowngradeEEvercore ISIOutperform → In-line$5+195.9%
Aug 11, 2026DowngradeCChardan Capital MarketsBuy → Neutral$5+195.9%
Jul 28, 2026InitiatedCCanaccord GenuityBuy$35+1,971.0%
Jul 22, 2026InitiatedEEvercore ISIOutperform$39+2,207.7%
Jun 22, 2026InitiatedCChardan Capital MarketsBuy$27+1,497.6%
Mar 17, 2026InitiatedCCantor FitzgeraldOverweight$35+1,971.0%
Sep 08, 2025InitiatedPPiper SandlerOverweight$20+1,083.4%
Oct 24, 2024InitiatedLLeerink PartnersOutperform$16+846.7%
Oct 14, 2024InitiatedGGuggenheimBuy$16+846.7%

Peers

Mkt cap
TickerCompanyMkt cap
GOSSGossamer Bio Inc71.44M
IKTInhibikase Therapeutics Inc227.44M
MISTMilestone Pharmaceuticals Inc82.44M
CYTKCytokinetics Inc8.15B
CVKDCadrenal Therapeutics Inc5.18M
TNYATenaya Therapeutics Inc84.61M
MNKDMannkind Corp1.35B
KARDKardigan Inc1.47B
MLYSMineralys Therapeutics Inc1.43B
LXRXLexicon Pharmaceuticals Inc832.59M

Insider trading

latest 14 of 27
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
ADAR1 Capital Management, LLC10% OwnerOct 21 '26Buy1.66331,979550,6877,447,000Oct 21 04:49 PM
ADAR1 Capital Management, LLC10% OwnerOct 19 '26Buy1.51336,528507,0136,860,679Oct 21 04:49 PM
ADAR1 Capital Management, LLC10% OwnerOct 20 '26Buy1.60254,342405,7267,115,021Oct 21 04:49 PM
Doogan DeclanDirectorSep 16 '26Buy1.9253,000101,76055,274Sep 17 09:30 PM
Giordano Christopher ThomasCEOSep 11 '26Buy1.886,00011,25017,324Sep 15 09:38 PM
Giordano Christopher ThomasCEOSep 15 '26Buy1.824,8508,83722,174Sep 15 09:38 PM
STAAB THOMAS R IIChief Financial OfficerSep 11 '26Buy1.945,67510,98115,675Sep 15 09:30 PM
ADAR1 Capital Management, LLC10% OwnerSep 03 '26Buy1.78900,0001,604,1606,524,151Sep 08 05:16 PM
ADAR1 Capital Management, LLC10% OwnerAug 31 '26Buy1.79403,571722,5945,257,389Sep 02 05:52 PM
ADAR1 Capital Management, LLC10% OwnerSep 02 '26Buy1.80187,704337,5865,624,151Sep 02 05:52 PM
ADAR1 Capital Management, LLC10% OwnerSep 01 '26Buy1.80179,058321,5705,436,447Sep 02 05:52 PM
ADAR1 Capital Management, LLC10% OwnerAug 21 '26Buy1.77716,3691,266,2544,746,444Aug 24 06:12 PM
ADAR1 Capital Management, LLC10% OwnerAug 20 '26Buy1.78202,124359,5384,030,075Aug 24 06:12 PM
ADAR1 Capital Management, LLC10% OwnerAug 24 '26Buy1.75107,374188,3554,853,818Aug 24 06:12 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B
DFACU.S. Core Equity 2 Portfolio-ETF Class SharesAUM: 49.14B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.310-0.358-3.1200.000.007
2026Q22026-07-31-0.350-0.381-0.3500.000.008
2026Q12026-05-12-0.350-0.397-0.3480.000.006
2025Q42026-03-10-0.380-0.414-0.3800.000.004
2025Q32025-11-12-0.400-0.313-0.3980.000.004
2025Q22025-08-13-0.270-0.266-0.2740.000.002
2025Q12025-05-14-0.280-0.193-0.2850.000.003
2024Q42025-03-25-0.180-0.425-0.1780.000.004
2024Q32024-11-13-0.190-1.369-0.1870.000.004
2024Q22024-08-13-1.830-1.985-1.8260.000.002
2024Q12024-05-14-3.120-2.400-3.1160.000.002
2023Q42024-03-28-11.140-9.990-10.8140.000.002
2023Q32023-11-14-6.610-7.200-6.6110.000.002
2023Q22023-08-15-4.000-8.000-4.0020.000.002
2023Q12023-05-15-12.000-29.600-12.1000.000.002
2022Q42023-03-30-127.2-212.4-88.9760.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2,160-2,800-2,1680.000.00
2020FY-2,128-1,352-2,1250.000.00
2021FY-2,528-2,600-2,5250.000.00
2022FY-643.2-744.8-600.720.000.00
2023FY-31.040-31.045-31.0350.000.00
2024FY-1.150-0.973-1.1530.000.00
2025FY-1.340-1.373-31.0400.000.00
2026FY--1.390--0.00
2027FY--1.308--0.00
2028FY--1.281--0.00
2029FY--1.070--37.33
2030FY--0.574--114.25

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-058000.000.000.00
2026Q4S2026-07-318000.000.000.00
2026Q4S2026-07-278000.000.000.00
2026Q4S2026-06-197000.000.000.00
2026Q4S2026-05-126000.000.000.00
2026Q4S2026-03-166000.000.000.00
2026Q4S2026-03-135000.000.000.00
2026Q4S2026-03-114000.000.000.00
2026Q4S2026-03-103000.000.000.00
2026Q4S2025-11-131000.000.000.00
2026Q4S2025-11-111000.000.000.00
2026Q4S2025-11-101000.000.000.00
2026Q4S2025-11-091000.000.000.00
2026Q4S2025-11-081000.000.000.00

Estimate history

EPS, annual-10026.24-14462.464-2167.888-2125.376-2525.072-600.72-31.035-1.153-1.341-1.3898
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.187-0.178-0.285-0.274-0.398-0.38-0.348-0.35-0.313
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.0010.0020.0040.0080.0160.0290.2983.4219.31445.536
Period201720182019202020212022202320242025MRQ
Shares, quarterly3.4093.4213.974.1485.9079.31424.27631.9545.536
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.010.110.110.110.110.01
Gross Profit0.000.000.00-0.01-0.11-0.11-0.11-0.11-0.01
Selling, General and Administrative Excl. Other69.5356.3819.498.2310.9432.629.758.456.88
Research and Development47.0032.6712.713.235.3825.154.563.471.24
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-69.53-56.38-19.49-8.23-11.05-32.73-9.87-8.56-6.89
Interest Expense0.000.000.020.020.000.000.000.000.00
Unusual Expense0.000.000.000.000.00-0.25-0.01-0.000.00
Net Income Before Taxes-65.76-52.60-17.60-7.71-11.05-32.47-9.85-8.39-6.81
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-65.76-52.60-17.60-7.71-11.05-32.47-9.85-8.39-6.81
Net Income From Continuing Operations-65.76-52.60-17.60-7.71-11.05-32.47-9.85-8.39-6.81
Net Income-65.76-52.60-17.60-7.71-11.05-32.47-9.85-8.39-14.14
EPS (Recurring)-1.23-1.34-1.15-31.04-600.71-2,538.53-2,126.43-2,168.24-14,462.47
EPS (Basic, Before Extraordinaries)-1.39-1.34-1.15-31.04-600.72-2,525.07-2,125.38-2,167.89-14,462.46
EPS (Diluted)-1.39-1.34-1.15-31.04-600.72-2,525.07-2,125.38-2,167.89-14,462.46
EBITDA-69.53-56.38-19.49-8.23-10.94-32.62-9.75-8.45-6.88
Non-Operating Income (Expense)3.773.791.920.550.010.010.010.160.08
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense14.5019.161.120.190.550.770.250.170.57
Shares Outstanding45.549.313.420.300.030.020.010.000.00
Market Capitalization76.9676.9621.106.553.3426.2223.479.514.59

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other17.7318.7816.5716.4516.8111.7911.347.29
Research and Development12.0712.8511.5410.5410.336.125.684.59
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-17.73-18.78-16.57-16.45-16.81-11.79-11.34-7.29
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-16.70-17.80-15.72-15.54-15.80-10.85-10.41-6.27
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-16.70-17.80-15.72-15.54-15.80-10.85-10.41-6.27
Net Income From Continuing Operations-16.70-17.80-15.72-15.54-15.80-10.85-10.41-6.27
Net Income-16.70-17.80-15.72-15.54-15.80-10.85-10.41-6.27
EPS (Recurring)-0.31-0.35-0.35-0.38-0.40-0.27-0.28-0.18
EPS (Basic, Before Extraordinaries)-0.31-0.35-0.35-0.38-0.40-0.27-0.28-0.18
EPS (Diluted)-0.31-0.35-0.35-0.38-0.40-0.27-0.28-0.18
EBITDA-17.73-18.78-16.57-16.45-16.81-11.79-11.34-7.29
Non-Operating Income (Expense)1.020.980.860.911.000.940.931.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.543.332.844.795.624.614.140.97
Shares Outstanding45.5431.9524.289.315.914.153.973.42
Market Capitalization76.96385.94274.9976.1134.7223.9026.0121.10

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments97.5694.859.792.125.586.715.4012.867.73
Short Term Receivables0.000.000.000.000.000.000.000.000.05
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets6.661.831.891.080.110.080.780.460.29
Total Current Assets104.2396.6911.683.215.696.806.1813.328.06
Net Property, Plant & Equipment0.000.000.000.190.290.060.180.010.01
Total Investments and Advances0.000.000.000.000.000.000.000.001.81
Intangible Assets0.000.00-------
Other Assets0.000.000.000.010.010.010.010.010.01
Total Assets104.2396.6911.683.405.996.876.3713.349.89
Short Term Debt Incl. Current Port. of LT Debt0.000.000.500.740.110.180.110.000.00
Accounts Payable6.043.162.070.450.860.761.660.750.00
Other Current Liabilities1.111.541.010.660.601.180.760.821.01
Total Current Liabilities7.164.693.591.851.562.122.531.571.01
Long Term Debt0.000.000.000.060.180.120.060.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities7.164.693.591.911.752.242.591.571.01
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.004E-060.000.00
Common Equity97.0791.998.101.494.244.633.7711.778.88
Total Shareholders Equity97.0791.998.101.494.244.633.7711.778.88
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity97.0791.998.101.494.244.633.7711.778.88
Total Liabilities & Stockholders Equity104.2396.6911.683.405.996.876.3713.349.89
Book Value Per Share10.4226.8927.1552.11269.43586.47895.304,966.4410,065.57
Tangible Book Value Per Share10.4226.8927.1552.11269.43586.47895.304,966.4410,065.57
Full-Time Employees166579910108
Price to Book Ratio0.710.220.580.846.185.072.520.391.36
Return on Assets-52.36-32.48-102.20-235.14-505.01-148.88-85.21-58.67-53.20
Return on Equity-55.64-35.17-160.79-385.12-732.21-234.61-108.01-65.98-67.94
Return on Invested Capital-54.19-19.13-95.22-709.59-733.34-207.41-219.01-57.88-99.53
Quick Ratio14.5620.603.261.743.643.212.448.517.99
Current Ratio14.5620.603.261.743.643.212.448.517.99

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-65.76-52.60-17.60-7.71-11.05-32.47-9.85-8.39-14.14
Depreciation--0.000.010.110.110.110.110.01
Other Funds (Non Cash)14.5019.161.150.220.3722.120.360.278.03
Funds from Operations-51.27-33.44-16.45-7.49-10.57-10.25-9.38-8.02-6.11
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.91-2.361.641.58-1.45-0.610.100.460.61
Cash from Operating Activities-49.35-35.80-14.81-5.90-12.01-10.86-9.27-7.56-5.50
Capital Expenditures0.000.000.000.00-0.00-0.01-0.00-0.00-0.01
Net Assets From Acquisitions0.000.000.000.00-0.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.00-0.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.460.020.007.36
Purchase of Investments0.000.000.000.000.00-0.35-0.60-0.62-0.49
Sale Or Maturity of Investments0.000.000.000.000.000.800.620.627.86
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.00-0.000.450.02-0.007.35
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock63.7138.51100.3714.197.939.7410.350.108.91
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock63.7138.51100.3714.197.939.7410.350.108.91
Proceedsfrom Stock Options0.000.000.000.007.939.198.660.008.91
Issuance or Reduction of Debt, Net0.000.00-0.50-0.620.620.000.240.000.00
Change in Long Term Debt0.000.000.000.000.620.000.240.000.00
Issuance of Long Term Debt0.000.000.000.000.620.000.240.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities63.7138.5199.8713.578.559.7410.600.108.91
Net Change in Cash14.362.7185.067.67-3.46-0.671.34-7.4610.76
Free Cash Flow-49.35-35.80-14.81-5.90-12.02-10.86-9.28-7.56-5.51
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments113.73117.98118.7597.5699.37105.46
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets3.293.694.426.663.440.40
Total Current Assets117.01121.66123.18104.23102.81105.86
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets117.01121.66123.18104.23102.81105.86
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable6.576.796.356.045.610.56
Other Current Liabilities1.781.282.141.110.991.97
Total Current Liabilities8.368.078.497.166.602.53
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities8.368.078.497.166.602.53
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity108.66113.59114.6997.0796.21103.33
Total Shareholders Equity108.66113.59114.6997.0796.21103.33
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity108.66113.59114.6997.0796.21103.33
Total Liabilities & Stockholders Equity117.01121.66123.18104.23102.81105.86
Book Value Per Share2.393.564.7210.4216.2924.91
Tangible Book Value Per Share2.393.564.7210.4216.2924.91
Full-Time Employees---16--
Price to Book Ratio0.713.081.530.750.310.21
Return on Assets-59.83-57.02-49.23-52.36-42.77-54.06
Return on Equity-64.20-59.80-51.71-55.64-44.80-56.12
Return on Invested Capital-15.37-15.67-13.70-16.01-16.43-10.50
Quick Ratio14.0115.0714.5214.5615.5841.89
Current Ratio14.0115.0714.5214.5615.5841.89

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-16.70-17.80-15.72-15.54-15.80-10.85
Other Funds (Non Cash)3.543.332.844.795.624.61
Funds from Operations-13.16-14.47-12.88-10.75-10.18-6.24
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.690.323.57-2.671.03-0.03
Cash from Operating Activities-12.48-14.15-9.31-13.41-9.15-6.26
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock8.2313.3730.5011.613.060.28
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock8.2313.3730.5011.613.060.28
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities8.2313.3730.5011.613.060.28
Net Change in Cash-4.25-0.7821.19-1.80-6.09-5.99
Free Cash Flow-12.48-14.15-9.31-13.41-9.15-6.26

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30-5.8M-5.61M
2026-10-1521.34%7.2M33.9M5.53M
2026-09-3021.20%7.2M33.9M5.46M
2026-09-1516.25%5.5M33.9M5.25M
2026-08-3129.63%9.3M31.3M4.48M
2026-08-1416.83%5.5M32.5M3.17M
2026-07-317.53%2.6M33.9M1.10M
2026-07-158.51%2.0M24.1M966.09K
2026-06-307.43%1.8M24.1M804.16K
2026-06-153.19%0.8M24.1M615.75K
2026-05-293.48%0.8M22.7M538.19K
2026-05-153.41%0.8M22.7M505.75K
2026-04-304.42%0.7M16.5M415.30K
2026-04-151.65%0.2M11.8M347.44K
2026-03-311.47%0.2M11.8M333.89K
2026-03-131.30%0.2M11.8M301.82K
2026-02-272.81%0.1M4.3M245.70K
2026-02-132.41%0.1M5.2M234.62K
2026-01-302.50%0.1M4.8M213.13K
2026-01-154.10%0.2M4.8M184.64K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.751.651.5025.7645.000.000.955-0.0090.000
call1.000.251.150.0010.2360.000.000.902-0.0080.000
call1.500.100.850.308.0987620.000.708-0.0260.001
call2.000.000.050.051.3541,31211.000.256-0.0070.001
call2.500.000.050.052.2842850.000.179-0.0090.001
call3.000.000.250.002.9260.000.000.151-0.0100.001
call3.500.000.950.003.4240.000.000.136-0.0110.001
call5.000.000.050.054.41550.000.000.114-0.0120.001
call7.500.000.050.005.4620.000.000.099-0.0140.000
put0.500.000.050.026.2751.000.00-0.045-0.0080.000
put1.000.000.050.0615.06130.000.00-0.080-0.0320.000
put1.500.000.400.105.08658.000.00-0.292-0.0260.001
put2.000.050.650.454.28514.000.00-0.747-0.0060.001
put2.500.401.200.735.85321.000.00-0.821-0.0090.001
put3.000.901.800.007.5890.000.00-0.849-0.0100.001
put3.501.402.300.008.1980.000.00-0.864-0.0110.001
put5.001.205.400.000.0000.000.00-0.886-0.0120.001
put7.503.607.900.000.0000.000.00-0.901-0.0140.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-19SEC
2026-10-15SCHEDULE 13G/ASEC
2026-10-13SCHEDULE 13G/ASEC
2026-10-09SCHEDULE 13G/ASEC
2026-10-088-KCurrent report2026-10-08SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-11SCHEDULE 13G/ASEC
2026-09-098-KCurrent report2026-09-09SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-08SCHEDULE 13GSEC
2026-09-08SCHEDULE 13G/ASEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-08-27SCHEDULE 13GSEC
2026-08-27SCHEDULE 13GSEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-243Initial statement of beneficial ownership of securities2026-08-20SEC
2026-08-18SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-12SCHEDULE 13G/ASEC
2026-08-108-KCurrent report2026-08-10SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-101.46M300
2026-092.40M700
2026-082.54M400
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-1296.41K500
2025-1193.11K700

Institutional holders

Manager% owned
Vivo Capital, LLC9.42%
BlackRock, Inc.6.51%
PERCEPTIVE ADVISORS LLC6.41%
VANGUARD CAPITAL MANAGEMENT LLC4.32%
MILLENNIUM MANAGEMENT LLC3.30%
Ikarian Capital, LLC2.97%
Candriam S.C.A.2.83%
CITADEL ADVISORS LLC2.75%
RTW INVESTMENTS, LP2.63%
Stonepine Capital Management, LLC2.49%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.21%
iShares Russell 2000 ETF2.45%
T. Rowe Price Health Sciences Fund, Inc.1.68%
Fidelity Advisor Biotechnology Fund1.68%
Nuveen Quant Small Cap Equity Fund1.63%
Fidelity Small Cap Discovery Fund1.26%
Fidelity Series Small Cap Discovery Fund1.13%
Fidelity Series Small Cap Core Fund1.06%
VANGUARD EXTENDED MARKET INDEX FUND1.05%
Fidelity Small Cap Index Fund1.04%

OakChart. TENX. Cached 15 minutes.